AstraZeneca demonstrates pipeline and portfolio strength across malignant and rare haematological diseases at EHA 2022
Calquence in combination with obinutuzumab shows longer-term overall survival at five years in 1st-line chronic lymphocytic leukaemia.Survival data will support long-term use of Ultomiris for the treatment of paroxysmal nocturnal haemoglobinuria.AstraZeneca will showcase data demonstrating the Company’s commitment to redefine care in haematology at the European Hematology Association (EHA) Annual Meeting, 9 to 12 June 2022. A total of five approved and potential new medicines from AstraZeneca will be featured across 16 abstracts, including one oral presentation. These include long-term